Gokcen Tugcu
Overview
Explore the profile of Gokcen Tugcu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Emiralioglu N, Cakir B, Sertcelik A, Yalcin E, Kiper N, Sen V, et al.
Pediatr Pulmonol
. 2024 Jul;
59(11):2956-2966.
PMID: 38980199
Background: The decline in pulmonary function is a predictor of disease progression in patients with cystic fibrosis (CF). This study aimed to determine the decline rate of percent predicted forced...
2.
Emeksiz Z, Metbulut P, Akyan Soydas S, Tugcu G, Cinel G, Misirlioglu E
Pediatr Allergy Immunol Pulmonol
. 2022 May;
35(2):74-78.
PMID: 35588286
Previous studies reported that the prevalence of drug allergy is higher in patients with cystic fibrosis (CF) than in the general population. It is important to exclude or confirm the...
3.
Bal Topcu D, Tugcu G, Er B, Eryilmaz Polat S, Hizal M, Yalcin E, et al.
Inflammation
. 2021 Oct;
45(2):627-638.
PMID: 34637032
We investigated plasma YKL-40 levels and chitotriosidase (CHIT1) activity in patients with cystic fibrosis (CF) lung disease and evaluated clinically relevant factors that may affect their levels. Plasma samples were...
4.
Emiralioglu N, Dogru D, Dogan O, Gulmez D, Arikan Akdagli S, Eryilmaz Polat S, et al.
Turk J Pediatr
. 2020 Aug;
62(4):560-568.
PMID: 32779408
Background And Objectives: Patients with cystic fibrosis (CF) have a varying spectrum of clinically significant Aspergillus disease in addition to allergic bronchopulmonary aspergillosis (ABPA). Here we aimed to review the...
5.
Cobanoglu N, Ozcelik U, Cakir E, Sismanlar Eyuboglu T, Pekcan S, Cinel G, et al.
Pediatr Pulmonol
. 2020 May;
55(9):2302-2306.
PMID: 32453906
Background: A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor. This cross-sectional study evaluated...
6.
Sismanlar Eyuboglu T, Dogru D, Cakir E, Cobanoglu N, Pekcan S, Cinel G, et al.
Pediatr Pulmonol
. 2020 May;
55(8):2011-2016.
PMID: 32364312
Background: Pseudo-Bartter syndrome (PBS) is a rare complication of cystic fibrosis (CF) and there are limited data in the literature about it. We aimed to compare clinical features and accompanying...
7.
Hizal M, Yalcin E, Alp A, Ozden M, Karakaya J, Eryilmaz Polat S, et al.
Pediatr Pulmonol
. 2020 Apr;
55(7):1646-1652.
PMID: 32227679
Background: Respiratory viruses (RVs) are frequently present in the airways of patients with cystic fibrosis (CF) during pulmonary exacerbations (PEx). Method And Objectives: This prospective, longitudinal study was performed to...
8.
Bal Topcu D, Tugcu G, Ozcan F, Aslan M, Yalcinkaya A, Eryilmaz Polat S, et al.
Lipids
. 2020 Mar;
55(3):213-223.
PMID: 32120452
We investigated plasma sphingomyelin (CerPCho) and ceramide (Cer) levels in pediatric patients with cystic fibrosis (CF) and primary ciliary dyskinesia (PCD). Plasma samples were obtained from CF (n = 19)...
9.
Dogru D, Cakir E, Sismanlar T, Cobanoglu N, Pekcan S, Cinel G, et al.
Pediatr Pulmonol
. 2019 Nov;
55(2):541-548.
PMID: 31710166
Background: Cystic fibrosis (CF) care has been implemented in Turkey for a long time; however, there had been no patient registry. For this purpose, the Turkish National CF Registry was...